KR20230026438A - Tlr4 작동 활성을 갖는 아쥬반트 - Google Patents

Tlr4 작동 활성을 갖는 아쥬반트 Download PDF

Info

Publication number
KR20230026438A
KR20230026438A KR1020237001883A KR20237001883A KR20230026438A KR 20230026438 A KR20230026438 A KR 20230026438A KR 1020237001883 A KR1020237001883 A KR 1020237001883A KR 20237001883 A KR20237001883 A KR 20237001883A KR 20230026438 A KR20230026438 A KR 20230026438A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
tetradecanoyl
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237001883A
Other languages
English (en)
Korean (ko)
Inventor
히토시 반
유스케 이마자키
요스케 다카나시
아키히사 후쿠시마
Original Assignee
스미토모 파마 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스미토모 파마 가부시키가이샤 filed Critical 스미토모 파마 가부시키가이샤
Publication of KR20230026438A publication Critical patent/KR20230026438A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/248—Colchicine radicals, e.g. colchicosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020237001883A 2020-06-22 2021-06-21 Tlr4 작동 활성을 갖는 아쥬반트 Pending KR20230026438A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020107194 2020-06-22
JPJP-P-2020-107194 2020-06-22
PCT/JP2021/023402 WO2021261444A1 (ja) 2020-06-22 2021-06-21 Ｔｌｒ４作動活性を有するアジュバント

Publications (1)

Publication Number Publication Date
KR20230026438A true KR20230026438A (ko) 2023-02-24

Family

ID=79281148

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237001883A Pending KR20230026438A (ko) 2020-06-22 2021-06-21 Tlr4 작동 활성을 갖는 아쥬반트

Country Status (15)

Country Link
US (1) US20230287027A1 (https=)
EP (1) EP4169527A4 (https=)
JP (1) JPWO2021261444A1 (https=)
KR (1) KR20230026438A (https=)
CN (1) CN116056721A (https=)
AU (1) AU2021295796A1 (https=)
BR (1) BR112022025969A2 (https=)
CA (1) CA3187828A1 (https=)
CL (1) CL2022003689A1 (https=)
IL (1) IL299253A (https=)
MX (1) MX2022016181A (https=)
PE (1) PE20230463A1 (https=)
PH (1) PH12022553464A1 (https=)
SA (1) SA522441781B1 (https=)
WO (1) WO2021261444A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026018889A1 (ja) * 2024-07-19 2026-01-22 住友ファーマ株式会社 ワクチンアジュバントを含むリポソーム製剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050399A1 (en) 1997-05-08 1998-11-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
WO2001034617A2 (en) 1999-11-12 2001-05-17 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE518874T1 (de) 1999-11-15 2011-08-15 Oncothyreon Inc Synthetische lipid-a analogen und verwendungen davon
CN101863930A (zh) 2003-01-06 2010-10-20 科里克萨有限公司 一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
US7807720B2 (en) 2007-02-01 2010-10-05 Panthera Biopharma, Llc Hydroxamic acid derivatives of 3-phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning
CN105188710A (zh) * 2013-03-15 2015-12-23 葛兰素史密丝克莱恩生物有限公司 包含缓冲的氨基烷基氨基葡糖苷磷酸酯衍生物的组合物及其用于增强免疫应答的用途
EP3242883A4 (en) * 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
JP7362667B2 (ja) * 2018-02-12 2023-10-17 イニミューン・コーポレーション Ｔｏｌｌ様受容体リガンド

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050399A1 (en) 1997-05-08 1998-11-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
WO2001034617A2 (en) 1999-11-12 2001-05-17 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J Biol Chem. 2004 Feb 6; 279(6):4440-9
Microbes Infect. 2002 Jul;4(8):837-51.
Nature. 2009 Apr 30;458(7242):1191-5.
Regul Toxicol Pharmacol. 2002 Jun;35(3):398-413.
서바릭스 인터뷰 폼

Also Published As

Publication number Publication date
CN116056721A (zh) 2023-05-02
BR112022025969A2 (pt) 2023-01-17
PE20230463A1 (es) 2023-03-14
EP4169527A4 (en) 2025-03-05
MX2022016181A (es) 2023-02-13
CL2022003689A1 (es) 2023-07-28
SA522441781B1 (ar) 2024-08-11
CA3187828A1 (en) 2021-12-30
US20230287027A1 (en) 2023-09-14
JPWO2021261444A1 (https=) 2021-12-30
IL299253A (en) 2023-02-01
WO2021261444A1 (ja) 2021-12-30
EP4169527A1 (en) 2023-04-26
PH12022553464A1 (en) 2024-03-04
AU2021295796A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
JP7195398B2 (ja) ピリミジン化合物
CN107531736B (zh) 脂质a模拟物、其制备方法和用途
CN110650729B (zh) 疫苗佐剂制剂
CN108348618B (zh) 腺嘌呤缀合物化合物及其作为疫苗佐剂的用途
JP7360385B2 (ja) ブラルテミシン類似体
KR20230171435A (ko) 훈련된 면역을 조절하기 위한 화합물 및 이의 사용 방법
JP7448954B2 (ja) ジアリールトレハロース化合物及びその使用
KR20230026438A (ko) Tlr4 작동 활성을 갖는 아쥬반트
WO2020204172A1 (ja) 水溶性アジュバント
WO2020204173A1 (ja) 水溶性アジュバントおよびそれを含有する組成物
HK40087565A (en) Adjuvant with tlr4 agonist activity
OA21080A (en) Adjuvant with TLR4 agonist activity.
JP2025514198A (ja) 二重機能免疫調節化合物、製剤、及びその使用
WO2025096619A1 (en) Dual functioning immune modulating compounds, formulations, and uses thereof
HK1258252B (en) Adenine conjugate compounds and their use as vaccine adjuvants
BRPI0807196A2 (pt) Método para prevenir ou inibir uma infecção bacteriana, vacina, composto, e, método para prevenir, tratar ou inibir a asma

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230117

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240613

Comment text: Request for Examination of Application